Biogen Inc (BIIB.O)
22 Jan 2018
BRIEF-Biogen Responds To Coverage Recommendation By The Canadian Drug Expert Committee (Cdec) For Spinraza
* BIOGEN RESPONDS TO COVERAGE RECOMMENDATION BY THE CANADIAN DRUG EXPERT COMMITTEE (CDEC) FOR SPINRAZA, THE ONLY TREATMENT APPROVED FOR TREATMENT OF 5Q SPINAL MUSCULAR ATROPHY (SMA)
Dec 21 Biogen Inc said on Thursday one of its drug to treat Alzheimer's disease failed to meet the main goal of a mid-stage trial, sending the drugmaker's shares down 4.3 percent in premarket trading.
* ADAPTIVE PHASE II STUDY OF BAN2401 IN EARLY ALZHEIMER’S DISEASE CONTINUES TOWARD 18-MONTH ENDPOINT
* BIOGEN AND IONIS ENTER INTO NEW COLLABORATION TO IDENTIFY NOVEL THERAPIES FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY
* BIOGEN APPOINTS MARK HERNON AS SVP, CHIEF INFORMATION OFFICER Source text for Eikon: Further company coverage:
* SARISSA CAPITAL MANAGEMENT'S ALEXANDER DENNER REPORTS PURCHASE OF 30,000 SHARES OF BIOGEN INC'S COMMON STOCK BETWEEN NOV 28-29 - SEC FILING Source text: (http://bit.ly/2niyLpi) Further company coverage:
Biogen Inc said on Monday it has licensed Alkermes Plc's multiple sclerosis (MS) drug, further boosting its position in the race for the next treatment amid slowing sales of its own flagship MS drug, Tecfidera.
Nov 27 Biogen Inc said on Monday it has licensed Alkermes Plc's multiple sclerosis (MS) drug, further boosting its position in the race for the next treatment amid slowing sales of its own flagship MS drug, Tecfidera.
* Appoints Jeff Capello as executive vice president and chief financial officer
* Acorda announces royalty monetization transactions for $53 million
|Johnson & Johnson (JNJ.N)||$148.14||--|
|Pfizer Inc. (PFE.N)||$36.93||--|
|Novartis AG (NOVN.S)||CHF83.92||+0.46|
|Merck & Co., Inc. (MRK.N)||$61.25||--|
|Roche Holding Ltd. (ROG.S)||CHF237.90||+2.10|
|Roche Holding Ltd. (RO.S)||CHF240.20||+1.80|
|Bayer AG (BAYGn.DE)||€108.94||+3.22|
|Bayer AG (BAYE.F)||--||--|
|Sanofi SA (SASY.PA)||€71.83||+1.00|
|GlaxoSmithKline plc (GSK.L)||1,373.20||+18.00|